Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1981 1
1982 1
1983 3
1984 4
1985 4
1986 2
1987 1
1988 2
1989 5
1990 4
1991 10
1992 10
1993 12
1994 9
1995 20
1996 17
1997 19
1998 22
1999 20
2000 34
2001 39
2002 59
2003 50
2004 64
2005 64
2006 73
2007 96
2008 111
2009 144
2010 127
2011 155
2012 215
2013 233
2014 290
2015 347
2016 338
2017 434
2018 480
2019 557
2020 621
2021 624
2022 735
2023 705
2024 314

Text availability

Article attribute

Article type

Publication date

Search Results

6,040 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant Hepatobiliary Neoplasm"
Page 1
Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Kelley RK, et al. J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009. J Hepatol. 2020. PMID: 31954497 Review.
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and in …
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglec …
Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?
Hou J, Karin M, Sun B. Hou J, et al. Nat Rev Clin Oncol. 2021 May;18(5):261-279. doi: 10.1038/s41571-020-00459-9. Epub 2021 Jan 19. Nat Rev Clin Oncol. 2021. PMID: 33469195 Free PMC article. Review.
Anti-inflammatory agents have the potential to not only prevent or delay cancer onset but also to improve the efficacy of conventional therapeutics and next-generation immunotherapies. Herein, we review the current clinical advances and experimental findings supporting the …
Anti-inflammatory agents have the potential to not only prevent or delay cancer onset but also to improve the efficacy of conventional thera …
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. Xu F, et al. J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4. J Exp Clin Cancer Res. 2018. PMID: 29843754 Free PMC article. Review.
Specific PD-1 blockades were approved for treatment of melanoma in 2014 and for treatment of non-small-cell lung cancer in 2015 in the United States, European Union, and Japan. Preclinical and clinical studies show immune checkpoint therapy provides survival benefit for gr …
Specific PD-1 blockades were approved for treatment of melanoma in 2014 and for treatment of non-small-cell lung cancer in 2015 in the Unite …
Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N. Roudko V, et al. Front Immunol. 2021 Sep 24;12:757804. doi: 10.3389/fimmu.2021.757804. eCollection 2021. Front Immunol. 2021. PMID: 34630437 Free PMC article. Review.
Defective DNA mismatch repair (dMMR) is associated with many cancer types including colon, gastric, endometrial, ovarian, hepatobiliary tract, urinary tract, brain and skin cancers. Lynch syndrome - a hereditary cause of dMMR - confers increased lifetime risk of maligna …
Defective DNA mismatch repair (dMMR) is associated with many cancer types including colon, gastric, endometrial, ovarian, hepatobiliary …
Surgery for cholangiocarcinoma.
Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Cillo U, et al. Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089. Liver Int. 2019. PMID: 30843343 Free PMC article. Review.
The sixth challenge is that even after a complete resection most patients develop recurrent disease. Recent randomized controlled trials found conflicting results regarding the benefit of adjuvant chemotherapy. ...
The sixth challenge is that even after a complete resection most patients develop recurrent disease. Recent randomized controlled tri …
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. Hack SP, et al. Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30. Future Oncol. 2020. PMID: 32352320 Free article.
We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary …
We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab p …
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Peng Z, et al. J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3. J Clin Oncol. 2023. PMID: 35921605 Clinical Trial.
MATERIALS AND METHODS: This was a multicenter, randomized, open-label, parallel group, phase III trial. Patients with primary treatment-naive or initial recurrent advanced HCC after surgery were randomly assigned (1:1) to receive LEN plus on-demand TACE (LEN- …
MATERIALS AND METHODS: This was a multicenter, randomized, open-label, parallel group, phase III trial. Patients with primary …
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.
Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. Adam R, et al. Cancer Treat Rev. 2015 Nov;41(9):729-41. doi: 10.1016/j.ctrv.2015.06.006. Epub 2015 Jun 30. Cancer Treat Rev. 2015. PMID: 26417845 Free article. Review.
Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide information on the tumour, margin size and micrometastases. Although the treatment strategy depends on the clinical scenario, the consensus w …
Pathological evaluation should assess response to preoperative chemotherapy for both the primary tumour and metastases, and provide informat …
Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.
Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT. Norton JA, et al. JAMA Surg. 2018 Mar 1;153(3):e175083. doi: 10.1001/jamasurg.2017.5083. JAMA Surg. 2018. PMID: 29365025 Free PMC article.
IMPORTANCE: Zollinger-Ellison syndrome (ZES) is a life-threatening disease caused by a malignant tumor that secretes gastrin (gastrinoma). Gastrinomas typically occur in the pancreas or the duodenum. ...Three patients (43%) remained free of disease at follow-up ranging fro …
IMPORTANCE: Zollinger-Ellison syndrome (ZES) is a life-threatening disease caused by a malignant tumor that secretes gastrin (gastrin …
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
Randomisation was performed by the minimisation method, using institution, primary tumour site, and lymph node metastasis as adjustment factors. ...For the S-1 group, all patients who began the protocol treatment were eligible for a safety assessment. This trial is …
Randomisation was performed by the minimisation method, using institution, primary tumour site, and lymph node metastasis as adjustme …
6,040 results